-
Je něco špatně v tomto záznamu ?
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020
SH. Lob, SP. Hawser, F. Siddiqui, I. Alekseeva, CA. DeRyke, K. Young, MR. Motyl, DF. Sahm
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- antibakteriální látky farmakologie terapeutické užití MeSH
- cefalosporiny terapeutické užití MeSH
- imipenem farmakologie terapeutické užití MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- pseudomonádové infekce * farmakoterapie mikrobiologie MeSH
- Pseudomonas aeruginosa MeSH
- tazobaktam farmakologie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
- Maďarsko MeSH
- Polsko MeSH
Antimicrobial susceptibility was determined for clinical gram-negative isolates from Czech Republic, Hungary, and Poland, where published data for ceftolozane/tazobactam (C/T) and imipenem/relebactam (IMI/REL) is scarce. C/T was active against 94.3% of Enterobacterales, 10-18% higher than the tested cephalosporins and piperacillin/tazobactam. IMI/REL was the most active tested agent against non-Morganellaceae Enterobacterales (99.7% susceptible). C/T was the most active among all studied agents except colistin against Pseudomonas aeruginosa (96.0% susceptible); susceptibility to IMI/REL was 90.7%. C/T maintained activity against 73.7-85.3% of β-lactam-resistant or multidrug-resistant P. aeruginosa subsets. C/T and IMI/REL could represent important treatment options for patients from these countries.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003962
- 003
- CZ-PrNML
- 005
- 20230425141018.0
- 007
- ta
- 008
- 230418s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10096-023-04549-1 $2 doi
- 035 __
- $a (PubMed)36670243
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Lob, Sibylle H $u IHMA, Schaumburg, IL, USA. shlob@ihma.com $1 https://orcid.org/0000000268290302
- 245 10
- $a Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020 / $c SH. Lob, SP. Hawser, F. Siddiqui, I. Alekseeva, CA. DeRyke, K. Young, MR. Motyl, DF. Sahm
- 520 9_
- $a Antimicrobial susceptibility was determined for clinical gram-negative isolates from Czech Republic, Hungary, and Poland, where published data for ceftolozane/tazobactam (C/T) and imipenem/relebactam (IMI/REL) is scarce. C/T was active against 94.3% of Enterobacterales, 10-18% higher than the tested cephalosporins and piperacillin/tazobactam. IMI/REL was the most active tested agent against non-Morganellaceae Enterobacterales (99.7% susceptible). C/T was the most active among all studied agents except colistin against Pseudomonas aeruginosa (96.0% susceptible); susceptibility to IMI/REL was 90.7%. C/T maintained activity against 73.7-85.3% of β-lactam-resistant or multidrug-resistant P. aeruginosa subsets. C/T and IMI/REL could represent important treatment options for patients from these countries.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a pseudomonádové infekce $x farmakoterapie $x mikrobiologie $7 D011552
- 650 _2
- $a antibakteriální látky $x farmakologie $x terapeutické užití $7 D000900
- 650 _2
- $a cefalosporiny $x terapeutické užití $7 D002511
- 650 _2
- $a tazobaktam $x farmakologie $x terapeutické užití $7 D000078142
- 650 _2
- $a Pseudomonas aeruginosa $7 D011550
- 650 _2
- $a imipenem $x farmakologie $x terapeutické užití $7 D015378
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 651 _2
- $a Česká republika $7 D018153
- 651 _2
- $a Polsko $7 D011044
- 651 _2
- $a Maďarsko $7 D006814
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hawser, Stephen P $u IHMA, Monthey, Switzerland
- 700 1_
- $a Siddiqui, Fakhar $u Merck & Co., Inc., NJ, Rahway, USA
- 700 1_
- $a Alekseeva, Irina $u MSD, Dubai, United Arab Emirates
- 700 1_
- $a DeRyke, C Andrew $u Merck & Co., Inc., NJ, Rahway, USA
- 700 1_
- $a Young, Katherine $u Merck & Co., Inc., NJ, Rahway, USA
- 700 1_
- $a Motyl, Mary R $u Merck & Co., Inc., NJ, Rahway, USA
- 700 1_
- $a Sahm, Daniel F $u IHMA, Schaumburg, IL, USA
- 773 0_
- $w MED00001612 $t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology $x 1435-4373 $g Roč. 42, č. 3 (2023), s. 365-370
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36670243 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141015 $b ABA008
- 999 __
- $a ok $b bmc $g 1924558 $s 1190171
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 42 $c 3 $d 365-370 $e 20230121 $i 1435-4373 $m European journal of clinical microbiology & infectious diseases $n Eur J Clin Microbiol Infect Dis $x MED00001612
- LZP __
- $a Pubmed-20230418
